Orphinic is an innovative drug development company focused on mid market opportunities and orphan drugs in late preclinical research and phase 1/2 of clinical trials. The company partners with IP owners leading research execution. It is currently building a porfolio of more than 10 projects. It uses AI/machine learning tools for project selection and execution.